top of page

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510.


Synendos transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders.





Recent Posts

See All

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord

October 2022 // Company

Synendos Therapeutics has been awarded with the Innosuisse Certificate Synendos has been awarded the Innosuisse certificate by Innosuisse Innovation Council. The Innosuisse certificate reflects remark

Comments


bottom of page